Source link : https://newshealth.biz/health-news/tolerability-concerns-for-glp-1-glucagon-agonist-in-obesity-masld/
NEW ORLEANS — Treatment with survodutide led to significant weight loss and reductions in liver fat in phase III trials of obesity and metabolic dysfunction-associated steatotic liver disease (MASLD), but about a fifth of patients quit the investigational glucagon and GLP-1 receptor dual agonist due to adverse events. Obesity Trial In the SYNCHRONIZE-1 trial of […]
The post Tolerability Concerns for GLP-1/Glucagon Agonist in Obesity, MASLD first appeared on News Health.
—-
Author : News Health
Publish date : 2026-06-08 21:07:00
Copyright for syndicated content belongs to the linked Source.
—-
1 – 2 – 3 – 4 – 5 – 6 – 7 – 8